IL15 and plasma cell myeloma: The resulting IL-15 DCs (6 days) exhibited outstanding activation of autologous T cells, CIK cells, and NK cells, and demonstrated strong cytolytic activity against both myeloma cell lines and patient autologous primary myeloma cells.